S04E015 скачать в хорошем качестве

S04E015

I sat down with Biosynth's CEO Urs Spitz earlier this week as part of my #ReflectionsandForecats 22/23 interview series. As yo will see we covered a wide range of topics, from the supply of #RawMaterials for Pharma, #Peptides, acquiring and integrating new businesses, BREXIT, the impact of the Capital markets on Biotechs and Pharma, Supply Chain and more. I asked Urs.... 2022 Reflections Can you give me a quick overview of Biosynth? 00:50 One word to describe 2022 and why? 02:50 What were some of Biosynth’s achievements in 2022 and who the companies Biosynth acquired in 2022 and why? 03:47 Looking back at 2022 what challenges did you see the sector face, and developments stood out for you? 05:56 How have Biosynth been able to manage the Supply Chain challenges? 08:22 Has BREXIT impacted the business and how? 11:00 Are there any areas you think the industry could improve? 12:50 2023 Forecasts What are your predictions for Pharma and Diagnostics industries in 2023? 15:07 Are there any technologies out here that you are excited about? 17:55 What developments and trends do you expect to see/predict in the supply of Chemical Products and Peptides? 20:50 What can we expect from Biosynth in 2023? 23:48 What learnings can Urs share with regards with regards integrating a new business to an existing one? 27:07 Finally, what last thoughts would you like to leave viewers with for 2023? Feel free to leave any questions or comments for Urs below the video. You can learn about Biosynth and their businesses at https://www.biosynth.com/ and https://www.biosynth.com/about-us #RSKBiosynth #ReflectionsandForecasts20222023, #RSKFeb23 #lifesciences #firstideatofinishedproduct #chemicalindustry